Navigation Links
Vion Reports 2007 Third Quarter and Nine-Month Results
Date:11/7/2007

Company Updates Status of Cloretazine(R) (VNP40101M) Clinical Trials in AML

NEW HAVEN, Conn., Nov. 7 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq Capital Market: VION) today announced results for the three-month and nine-month periods ended September 30, 2007.

The Company reported a net loss of $9.0 million, or $0.13 per share, for the three-month period ended September 30, 2007, compared to a net loss of $6.3 million, or $0.10 per share, for the same period in 2006. Weighted- average common shares outstanding for the three months ended September 30, 2007 and 2006 were 67.7 million and 66.2 million, respectively.

For the nine-month period ended September 30, 2007, the net loss was $25.8 million, or $0.39 per share, compared to a net loss of $19.2 million, or $0.29 per share, for the same period in 2006. Weighted-average common shares outstanding for the nine months ended September 30, 2007 and 2006 were 66.8 million and 66.2 million, respectively.

Total operating expenses were $8.6 million and $6.8 million for the three months ended September 30, 2007 and 2006, respectively, and $25.1 million and $20.8 million for the nine months ended September 30, 2007 and 2006, respectively.

In the quarter, the increase in operating expenses was due to higher total research and development expenses resulting from: (i) late-stage clinical development of Cloretazine(R) (VNP40101M), including additional personnel, drug production costs and other costs in support of a potential registration filing and (ii) stock-based compensation expense. In addition, marketing, general and administrative expenses were higher than the prior year quarter, primarily due to increased medical advisory board meetings and stock-based compensation expense.

In the nine-month period, the increase in operating expenses was due to higher total research and development expenses resulting from: (i) late-stage clinical development of Cloretazine(R) (VNP40101
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
2. Haemacure Reports Third Quarter 2007 Results
3. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
4. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
5. MDS Reports Third Quarter 2007 Results
6. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
7. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
8. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
9. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
10. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
11. AdCare Health Systems, Inc. Reports Discontinuation of Definitive Merger Agreement with Family Home Health Services, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... conducted by researchers at Tufts University School of Dental ... and developmental disabilities, the likelihood of having cavities decreased ... The findings, published in the July/August issue of ... designed to address the oral health of individuals in ... records of 107 patients at one of the eight ...
(Date:7/9/2014)... , , , , , ... , , , , ... assault rifle and the microphone is 50m downrange from the firer and approximately 30cm from the bullet... , ... , , , , , ... , , , , , , ...
(Date:7/9/2014)... Keck School of Medicine of the University of ... a specific component of the immune system are ... of infection. The discovery suggests that blocking this ... human autoimmune and hyper-inflammatory diseases such as rheumatoid ... was published online on June 23 in ...
(Date:7/8/2014)... Calif. The Department of Defense,s Defense Advanced ... Laboratory (LLNL) up to $2.5 million to develop ... record and stimulate neurons within the brain to ... , The research builds on the understanding that ... certain regions of the brain encode information, store ...
(Date:7/8/2014)... 2014 In a study published yesterday in the ... La Jolla Institute (LJI) led by Pandurangan Vijayanand, Ph.D. identify ... currently affects over 200 million people world wide. , ... be divided into small sections or ,neighborhoods., Scientists can ... primed for gene production, by looking for a marker on ...
Breaking Medicine News(10 mins):Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 3Health News:LJI develops new approach to identify genes poised to respond in asthma patients 2
... 6 million international research consortium to strengthen knowledge of how ... most effectively rebuilt. The REBUILD programme, funded ... will focus on health financing, human resources and their interaction. ... aim to build knowledge about the implications for women, girls ...
... dialysis see their lives inevitably affected by the treatment. ... these kidney patients has improved very little, although it ... starting point, Dr Begoa Ruiz de Alegra studied the ... treatment and domiciliary peritoneal dialysis) in the Basque Country ...
... medicine is one of today,s most exciting scientific and ... ,firsts, new rulings by regulatory bodies or ethical controversies. ... the field, ethicists, legislators, the media and the public. ... than 9,000 of the world,s leading experts in reproductive ...
... People with immune-related disorders such as rheumatoid arthritis and lupus ... clots during hospital stays, a new study has found. ... analyzed 45 years, worth of medical records of patients who ... prior history of blood clots in a vein, also called ...
... research from UC Davis Cancer Center has found that whether ... where they live in addition to their race or ethnicity. ... lower colorectal screening rates than whites, presumably because of differences ... hasn,t been known, until now, is whether these differences also ...
... blood tests require shipping a vial of blood to a laboratory ... device invented by a team of engineers and students at the ... a portable device that provides results in less than 30 minutes. ... testing can be performed in a clinic, in a doctor,s office, ...
Cached Medicine News:Health News:LSTM leads new £6 million ($9.3 million) health systems knowledge consortium 2Health News:Ph.D. thesis shows why patients subjected to dialysis face their illness in different ways 2Health News:Ph.D. thesis shows why patients subjected to dialysis face their illness in different ways 3Health News:ESHRE bridges East and West for its 2012 Congress in Istanbul 2Health News:Immune Disorders May Raise Blood Clot Risk in Hospitalized Patients 2Health News:For non-whites, geography plays key role in colon cancer screening 2Health News:For non-whites, geography plays key role in colon cancer screening 3Health News:Engineering team invents lab-on-a-chip for fast, inexpensive blood tests 2
(Date:1/15/2014)...  Humberto C. Antunes,  Galderma  worldwide CEO, will receive a ... of Drugs in Dermatology (JDD) at the upcoming ... is January 17-20, 2014, at the Omni Orlando Resort at ChampionsGate ... The ODAC is a distinguished event that delivers a ...
(Date:1/15/2014)... 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... patent application concerning composition of matter, biological targets, mechanism ... cell death.  This patent application describes ... RNA molecules (VSRNAs) which interfere with the basic homeostatic ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
24-Well Slot Blot...
... Disposable, clear, APET plastic tray. Ideal for ... those trays used for multipurposes. Pour spouts ... A marker or label may be used ... trays on rockers or shakers for staining ...
... with vacuum stage, porous vacuum plate, reservoir seal ... The Model 785 vacuum blotter quickly and ... gel onto a nylon membrane. Because it generally ... acid samples can be separated on a gel, ...
... vacuum stage, porous vacuum plate, reservoir seal O-ring, ... The Model 785 vacuum blotter quickly and efficiently ... onto a nylon membrane. Because it generally requires ... samples can be separated on a gel, transferred ...
Medicine Products: